Lyell Immunopharma is a clinical-stage cell therapy company that develops T-cell reprogramming technologies for patients with solid tumors. Its pipeline includes genetically and epigenetically reprogrammed CAR T-cell product candidates for the treatment of various solid tumors. The company was incorporated in 2018 and is headquartered in South San Francisco, California.